BOSTON – We all know that exercise is good for us and that being fit can lower our risk of heart disease and possibly help us to live longer, but what amount and type of physical activity can change a person’s fitness level? New research led by investigators at Massachusetts General Hospital (MGH) and Boston University and published in the European Heart Journal provides some specifics.
The research looked at cardiorespiratory fitness, or the capacity of the heart and lungs to supply oxygen to the body’s muscles during physical activity, in 2,070 participants from the Framingham Heart Study, a long-running multigenerational study designed to identify factors that contribute to cardiovascular disease. Participants underwent tests of physiologic parameters during exercise and wore physical activity trackers for a week at one point, then again nearly eight years later.
In this analysis, investigators found that people who increased their steps per day, participated in a greater amount of moderate-to-vigorous physical activity, or reduced their sedentary time between the two exams showed improvements in distinct aspects of cardiorespiratory fitness throughout exercise sessions, from warm-up to peak exercise to recovery. These findings were largely consistent regardless of participants’ baseline activity level, age, sex, weight, and risk of heart disease.
For each minute of increase in average moderate-to-vigorous physical activity, more than 3 minutes of intermediate cadence walking or 14.6 fewer minutes of sedentary time would be required for the equivalent changes in fitness. Also, increasing moderate-to-vigorous physical activity by 17 minutes per day, taking an additional 4,312 steps per day (approximately 54 minutes at 80 steps per minute), or reducing 249 minutes of sedentary time per day between the two exams corresponded to a 5% higher peak VO2, or peak oxygen uptake. Individuals with higher than the average number of steps or higher than the average amount of moderate-to-vigorous physical activity among the study participants also had above average peak VO2 values regardless of how much sedentary time they had during the day.
“We conducted this analysis to understand relative effects of changing sedentary activity, low-level physical activity, and moderate-to-vigorous activity on multiple domains of exercise capacity as objectively measured by cardiopulmonary exercise testing,” says senior author Gregory D. Lewis, MD, who is director of the Cardiopulmonary Exercise Testing Laboratory at MGH and medical director of MGH’s Heart Failure and Cardiac Transplantation Program. “The results offer adults equivalents of how much reduction in sedentary time, walking, or moderate-to-vigorous exercise will translate to changes in exercise capacity, which in turn are known to strongly predict long-term health status.”
“The most surprising finding of our study was that individuals with higher-than-average steps per day or moderate-to-vigorous physical activity had higher-than-average fitness levels regardless of how much time they spent sedentary. This would indicate that much of the negative effect that being sedentary has on fitness may be offset by also having higher levels of activity and exercise,” says the study’s first author, Matthew Nayor, MD, MPH, the Aram Chobanian Assistant Professor of Medicine in the Sections of Cardiovascular Medicine and Preventive Medicine and Epidemiology at Boston University Medical Center.
“Physical activity is a cornerstone for modern cardiovascular disease prevention,” says study co-senior author Ravi Shah, MD, director of Clinical and Translational Research in Cardiology at Vanderbilt. “These results support ongoing efforts to improve activity as a means to improve overall cardiometabolic health.”
###
Co-authors of the study include Ariel Chernofsky, Nicole L. Spartano, Melissa Tanguay, Jasmine B. Blodgett, Venkatesh L. Murthy, Rajeev Malhotra, Nicholas E. Houstis, Raghava S. Velagaleti, Joanne M. Murabito, Martin G. Larson, and Ramachandran S. Vasan.
The Framingham Heart Study is affiliated with Boston University and supported by the National Heart, Lung and Blood Institute. This work was supported by the National Institutes of Health and the American Heart Association.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2021, Mass General was named #5 in the U.S. News & World Report list of "America’s Best Hospitals."
Journal
European Heart Journal
Method of Research
Experimental study
Subject of Research
People
Article Title
Physical activity and fitness in the community: the Framingham Heart Study
Article Publication Date
26-Aug-2021
COI Statement
R.V.S. is supported in part by grants from the National Institutes of Health and the American Heart Association. In the past 12 months, R.V.S. has served as a consultant for Myokardia (ongoing) and Best Doctors (ongoing), receives research funding from Amgen (concluded), and had minor stock holdings in Gilead, and his spouse has current stock holdings in Pfizer. R.V.S. is a co-inventor on a patent for ex-RNAs signatures of cardiac remodelling. G.D.L. acknowledges research funding from the National Institutes of Health and the American Heart Association as well as Amgen, Cytokinetics, Applied Therapeutics, AstraZeneca, and Sonivie in relation to projects and clinical trials investigating exercise capacity that are distinct from this work. He has served as a scientific advisor for Pfizer, Merck, Boehringer-Ingelheim, Novartis, American Regent, Relypsa, Cyclerion, Cytokinetics, and Amgen and receives royalties from UpToDate for scientific content authorship related to exercise physiology. N.L.S. acknowledges research support from the Alzheimer’s Association and has also received funding from Novo Nordisk for a MD-initiated research grant unrelated to the current paper. J.M.M. has served as a guest lecturer/consultant at Merck. The other authors report no conflicts of interest.